What does the evidence show about Pterostilbene's effects?

Read Off Label rates the evidence for Pterostilbene as Weak-Preclinical and the benefit magnitude as low-med / varies, producing an overall grade of C- (4.5/10). Paired with NR in EH301 trial — modest ALS functional improvement.

What safety findings are reported for Pterostilbene?

Pterostilbene has a low-med risk profile in the database. Low-Med (LDL elevation reported) Legal status: OTC.

Rankings / Longevity — Senolytics & Polyphenols

Pterostilbene

Longevity · Polyphenol

Tier C-

Reviewed by Read Off Label · Last reviewed Jun 8, 2026 · How we grade

ampkpolyphenolanti-inflammatoryotc

4.5 / 10

Tier C-

Ev 2.5 Bn 3.5 Sf 7

Bottom line

Read Off Label grades Pterostilbene as C- (4.5/10) based on weak-preclinical evidence, low-med / varies benefit magnitude, and a low-med-risk safety profile.

Paired with NR in EH301 trial — modest ALS functional improvement.

Studied, labeled, or reported-use context: 50-250 mg/day — OTC; not individualized guidance.

What the evidence says

Paired with NR in EH301 trial — modest ALS functional improvement. Better absorbed than resveratrol in theory but limited direct head-to-head human data. Often combined with nicotinamide riboside (e.g., Basis, Niagen+).

Mechanism

Dimethylated resveratrol analog; better oral bioavailability (~80% vs 1%); SIRT1 activator; AMPK activator; anti-inflammatory

Studied, labeled, or reported dose & route

50-250 mg/day

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Pterostilbene's effects?: Read Off Label rates the evidence for Pterostilbene as Weak-Preclinical and the benefit magnitude as low-med / varies, producing an overall grade of C- (4.5/10). Paired with NR in EH301 trial — modest ALS functional improvement.
What safety findings are reported for Pterostilbene?: Pterostilbene has a low-med risk profile in the database. Low-Med (LDL elevation reported) Legal status: OTC.
What doses or routes are reported for Pterostilbene?: 50-250 mg/day This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Pterostilbene work?: Dimethylated resveratrol analog; better oral bioavailability (~80% vs 1%); SIRT1 activator; AMPK activator; anti-inflammatory

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.